Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery

Pain, Postoperative Clinical Trial

Official title:

A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02959476
• Other study ID #: 94006184
• Status: Completed
• Phase: Phase 3
• Start date: March 13, 2017
• Est. completion date: August 10, 2018

Study information

• Verified date: April 2018
• Source: BioQ Pharma, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates a Ropivacaine 0.2% Pre-Filled Dispenser in the treatment of post-surgical pain in patients undergoing Cesarean delivery. Half of the patients will receive Ropivicaine and half will receive placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 132
• Est. completion date: August 10, 2018
• Est. primary completion date: August 10, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Complete the informed consent process as documented by a signed informed consent form (ICF).

• Be in generally good health and classified as either PS-1 or PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.

• Have a single birth pregnancy. Can be parous or nulliparous.

• Be scheduled for a Cesarean Delivery

• Subjects undergoing emergency Cesarean Delivery will not be eligible for participation in this study.

• In the event a subject signs the ICF (but has not been randomized), has a C section planned and then has an emergency C section delivery, this subject will be considered a screen failure.

• In the unlikely event a subject signs the ICF and is randomized into the study, has a C section planned and then has an emergency C section delivery, this subject will continue in the study as planned.

• Be willing to complete the pain assessments according to the protocol and return to clinic as scheduled, as needed.

Exclusion Criteria:

• Have an uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude their participation in the study.

• Have a clinically significant abnormal electrocardiogram (ECG) at screening as determined by the Investigator.

• Have a history of any medical condition or surgical procedure that would alter the absorption, distribution, metabolism, or excretion of ropivacaine.

• Have, in the opinion of the investigator, a clinically significant abnormality in their clinical laboratory values (urinalysis, hematology and chemistry) at screening.

• Have made a donation (standard donation amount or more) of blood or blood products (with the exception of plasma as noted below) within 56 days prior to Day 1.

• Weigh greater than 100 kg (220 lbs).

• Have made a plasma donation within 7 days prior to Day -1.

• Have a known allergy or hypersensitivity to anesthetics (eg. Ropivacaine), acetaminophen, or non-steroidal anti inflammatory drugs (NSAIDs, eg, ibuprofen or naproxen, ketorolac).

• Not be able or willing to discontinue the prohibited medications listed below within the allotted time before surgery and throughout the duration of their participation in the study.

• monoamine oxidase inhibitors (MAOIs) within the past 30 days

• anticonvulsants, tricyclic antidepressants (TCAs), neuroleptics, serotonin-norepinephrine reuptake inhibitors (SNRIs), as well as selective serotonin reuptake inhibitors (SSRIs) (unless SSRIs have been prescribed for depression and/or anxiety and subjects have been on a stable dose for at least 30 days prior to the screening visit);

• Corticosteroids: Oral and injectable corticosteroids must be discontinued 3 months prior to surgery; nasal, inhaled and topical corticosteroids will be allowed;

• Use concurrent therapy that could interfere with the evaluation of efficacy or safety parameters in the opinion of the investigator (eg, any drugs, in the investigator's opinion, that may exert significant analgesic properties), except for rescue medications.

• Have a history of seizures or history of serious head injury.

• Must not be a member of a vulnerable population as defined by the Code of Federal Regulations Title 45, Part 46, Delivery 46.111(b), including but not limited to employees (temporary, part-time, full-time, etc.) or a family member of the research staff conducting the study, or of the Sponsor, or of the Clinical Research Organization.

• Have previously participated in a clinical trial using ropivacaine.

• Have a history of major mental illness that in the opinion of the Investigator may affect the ability of the subject to participate in the study. Institutionalized subjects will not be eligible for participation.

Related Conditions & MeSH terms

• Pain, Postoperative

Intervention

Drug:
• Ropivacaine
Anesthetic
• Placebos
Inactive comparator

Locations

Country	Name	City	State
United States	Compass Clinical Trial	Beaumont	Texas
United States	MedPharmics, LLC	Biloxi	Mississippi
United States	Clinical Research Associates, Inc.	Birmingham	Alabama
United States	Physician's Research Options, LLC- Corner Canyon OB/GYN	Draper	Utah
United States	Duke University Medical Center	Durham	North Carolina
United States	Clinical Research Prime	Idaho Falls	Idaho
United States	West Virginia University	Morgantown	West Virginia
United States	University of California, Irvine	Orange	California
United States	Health Sciences Center- University of Utah	Salt Lake City	Utah
United States	Shoals Medical Trials, Inc.	Sheffield	Alabama
United States	Vision Clinical Research	Wellington	Florida

Sponsors (2)

Lead Sponsor	Collaborator
BioQ Pharma, Inc.	Health Decisions

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative analgesic effect		48 hours
Secondary	Use of other analgesics		48 hours
Secondary	Local safety and tolerability using descriptive statistics of the evaluation of physical exams, wound healing and treatment-emergent adverse events local to the surgical wound		7 days
Secondary	Overall safety using descriptive statistics of the evaluation of physical exam, vital signs, clinical laboratory tests, and treatment-emergent adverse events		7 days
Secondary	Analgesic effect at specified intervals		48 hours